Short-term Investigation of Resveratrol on Fat Metabolism in Morbidly Obese Women Undergoing Gastric Bypass Surgery

University of Aarhus

Status: Unknown

Conditions: Obesity

Treatments: Other: Placebo; Dietary Supplement: Resveratrol

Study type: Interventional

Funder types: Other

Identifiers

NCT01826279

M-20110172B

Details and patient eligibility

About

The purpose of this study is to investigate potential metabolic effects of resveratrol in morbidly obese women undergoing gastric bypass surgery.

The investigators hypothesize that resveratrol will:

• Decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion
• Decrease hepatic and adipose tissue VLDL-TG uptake
• Increase insulin sensitivity

The investigators will look at changes in:

• Lipid turnover (VLDL-TG kinetics, palmitate kinetics,calorimetry)
• VLDL-TG uptake in different tissues (subcutaneous femoral adipose tissue, subcutaneous abdominal adipose tissue, visceral adipose tissue and liver tissue)
• Insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp)
• Regulation of liver fat handling
• Lipoprotein lipase activity and fat cell size (abdominal and femoral adipose tissue)

Enrollment: 16 estimated patients

Sex: Female

Ages: 25 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female
• 25-60 years
• Obesity (BMI > 35 kg/m2)
• Have at least one element of the metabolic syndrome either hypertension and/or hypercholesterolemia (high triglyceride, low HDL-cholesterol)
• Undergoing gastric bypass surgery
• Written informed consent

Exclusion criteria

• Any other relevant disease (e.g. diabetes, thyroid or parathyroid disease, heart, kidney or liver disease)
• May have arthrosis or depression
• Any present or previous malignancy
• History of smoking
• Alcohol dependency (more than 14 units of alcohol per week)
• Participation in studies with radioactive isotope within the last six months
• Hemoglobin under the normal range regarding to sex (under 7.3 mmol/l for women)

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

16 participants in 2 patient groups, including a placebo group

Resveratrol

Experimental group

Description:

Resveratrol 500mg 3 times daily for 1 month

Treatment:

Dietary Supplement: Resveratrol

Placebo

Placebo Comparator group

Description:

Placebo 1 tablet 3 times daily for 1 month

Treatment:

Other: Placebo